For many years, it was thought that bacterial products caused fever via the intermediate production of a host-derived, fever-producing molecule, called endogenous pyrogen (EP). Bacterial products and other fever-producing substances were termed exogenous pyrogens. It was considered highly unlikely that exogenous pyrogens caused fever by acting directly on the hypothalamic thermoregulatory center since there were countless fever-producing microbial products, mostly large molecules, with no common physical structure. In vivo and in vitro, lipopolysaccharides (LPSs) and other microbial products induced EP, subsequently shown to be interleukin-1 (IL-1). The concept of the 'endogenous pyrogen' cause of fever gained considerable support when pure, recombinant IL-1 produced fever in humans and in animals at subnanomolar concentrations. Subsequently, recombinant tumor necrosis factor-α (TNF-α), IL-6 and other cytokines were also shown to cause fever and EPs are now termed pyrogenic cytokines. However, the concept was challenged when specific blockade of either IL-1 or TNF activity did not diminish the febrile response to LPS, to other microbial products or to natural infections in animals and in humans. During infection, fever could occur independently of IL-1 or TNF activity. The cytokine-like property of Toll-like receptor (TLR) signal transduction provides an explanation by which any microbial product can cause fever by engaging its specific TLR on the vascular network supplying the thermoregulatory center in the anterior hypothalamus. Since fever induced by IL-1, TNF-α, IL-6 or TLR ligands requires cyclooxygenase-2, production of prostaglandin E 2 (PGE 2 ) and activation of hypothalamic PGE 2 receptors provides a unifying mechanism for fever by endogenous and exogenous pyrogens. Thus, fever is the result of either cytokine receptor or TLR triggering; in autoimmune diseases, fever is mostly cytokine mediated whereas both cytokine and TLR account for fever during infection.
CYTOKINES AS ENDOGENOUS PYROGENS AND BACTERIAL PRODUCTS AS EXOGENOUS PYROGENS
The definitions have not changed since the early research of Beeson and Atkins. In fact, Beeson's classic abstract in 1948 1 and Atkins' landmark review 2 still stand as hallmarks in the field. Research on the pathogenesis of fever by Barry Wood, Elisha Atkins, Phyllis Bodel, Sheldon Wolff and Sheldon Greisman heralded what today is called 'cytokine biology'. Certain cytokines are true endogenous pyrogens, other cytokines are by-stander endogenous pyrogens, and all bacterial products and foreign antigens are exogenous pyrogens. Each induces a febrile response, the hallmark of infection since recorded history. But what has changed? The discovery of the existence of a large family of mammalian receptors termed Toll-like receptors (TLRs), which are expressed on various cells, explains how microbial products of varied chemical and physical characteristics can evoke the same biological response, fever. The recognition that the endotoxins from Gram-negative bacteria signal via one of these receptors 3 provided a platform for understanding how microbial products cause fever in the post-TLR world. It is of considerable relevance to the pathogenesis of fever that the cytoplasmic domains of TLR share with the cytoplasmic domain of IL-1 receptors the same ancient signaling areas. 4 It is also important that the signaling cascade of IL-1, TNFα, IL-6 and other pyrogenic cytokines share a common pathway to activate of nuclear factor-κB (NF-κB).
There was a dilemma as to how to explain the varied chemical and unrelated physical characteristics of exogenous pyrogens resulted in fever. There was no unifying mechanism linking their physical dissimilarities. How could there be a similar number of specific receptors to bind each of the exogenous pyrogens? The induction of the intermediate production of an endogenous pyrogen provided a common pathway. Only a few specific receptors would be needed for endogenous pyrogens. However, there was one common linkage that was shared by nearly all fever-producing substances: the production of prostaglandin E 2 (PGE 2 ). The second discovery, which linked exogenous pyrogens of varied chemical and physical properties to fever, was the importance of cyclooxygenase-2 (COX-2) to the febrile response, regardless of the evoking pyrogen. In mice deficient in COX-2, fever does not develop following injection of peripheral or central nervous system LPS, IL-1, TNF-α or IL-6. [5] [6] [7] [8] Each of ligands for TLR as well as the pyrogenic cytokines IL-1 and TNF-α result in NF-κB activation with COX-2 expression and PGE 2 synthesis. The third discovery was the existence of four specific receptors for PGE 2 in the brain and the identification that one of these, PGE 2 receptor 3 (EPR-3) is required to develop fever by IL-1β, LPS or PGE 2 . 9, 10 There appears, however, a single exception to requirement of PGE 2 for fever and that is one of the chemokines, macrophage inflammatory protein-1β, which produces fever via a PGE 2 -independent pathway, whereas another chemokine termed 'regulated on activation, normal T-cells expressed and secreted' (RANTES) produces fever via a PGE 2 -dependent pathway. 11 Since TLRs signal via the same intracellular pathways as do IL-1 receptors, the dissimilar extracellular domains link the world of microbial products and the biology of mammalian cytokines in a fashion that broadens the mechanisms by which the host can increase body temperature in response to infection. Clearly, nature has imparted to the fever-producing processes several different receptor-mediated events converging on the intracellular signal. The extracellular domains of the IL-1, TNF, and IL-6 as well as TLR-2 and TLR-4 are unrelated. As shown in Figure 1 , reaching the rich endothelial network called the organ vasculosum laminia terminalis (OVLT), ligands such as cytokines and any microbial products bind and activate their respective receptors on the blood side of the anterior hypothalamus. There is no evidence that cytokines or microbial products arriving via the internal carotid artery at the anterior hypothalamic area pass the blood brain barrier during the time course of fever induction. Rather, the induction of fever begins with the activation of cyclooxygenase-2 (COX-2) and release of PGE 2 on the brain side of these vessels.
The fundamental event in raising core temperature is to increase the thermostat in the hypothalamus to a higher level. This is accomplished by stimulating specific neural networks via neurotransmitters released in response to pyrogens. Specifically, it is the ability of PGE 2 to activate EPR-3 and initiate the neurotransmitter cascade. For example, PGE 2 induces hypothalamic cAMP, which can act as a neurotransmitter and contributes to raising the thermostatic set-point. 12, 13 Other neural networks exist such as those triggered by the peripheral vagus nerve 14 and is discussed below. In addition, there is a role of opiate receptors 15 and angiotensin II receptors in the central control of fever production. 16, 17 The neural networks for regulating a febrile response are discussed in reviews by Saper. 18, 19 However, this review will focus on unifying mechanisms by which several cytokines with different receptors and countless microbial products with unrelated structures cause fever. In addition, how fever associated with autoimmune disease and how fever during infection is affected by anticytokine therapies is discussed.
NEW TERMINOLOGY
With the acceptance of the term 'cytokine' and the interleukin nomenclature, the term endogenous pyrogen is no longer appropriate. It is more appropriate to assign to a special class of cytokines that are intrinsically pyrogenic the term pyrogenic cytokines rather than call them endogenous pyrogens. The value of this nomenclature is that it differentiates cytokines that are intrinsically pyrogenic from those which are not intrinsically pyrogenic. Cytokines are small, non-structural proteins in the molecular weight range 10-30 kDa. They possess potent biological activities and are usually produced in disease states or following antigenic challenge rather than in health. They are also essential for a functional immune system. Cytokines are also classed broadly into proinflammatory cytokines and anti-inflammatory cytokines. For example, pro-inflammatory cytokines include IL-1, TNF-α, IL-6, IL-12 and IL-18 whereas anti-inflammatory cytokines include IL-4, IL-10 and IL- 13 . Each cytokine is the product of a separate gene and each cytokine activates cells via its own highly specific surface receptor. Cytokine receptors are expressed on most cells, which accounts for their role in several biological and pathological processes.
To date, the following cytokines are intrinsically pyrogenic in that they produce a rapid onset fever within minutes: they are IL-1α, IL-1β, TNF-α, 20 TNF-β, IL-6 21 and ciliary neurotrophic factor (CNTF). 22 Although interferon-α (IFN-α) and to a lesser extent IFN-γ cause fever in humans and rabbits, 23 the onset of interferon fever occurs several hours after the injection and it is unclear whether interferons are intrinsically pyrogenic cytokines. The fever that accompanies IFN-α therapy responds to routine antipyretics. In the case of IFN-γ fever, the mechanism for the febrile effect is unclear Infection, fever, and exogenous and endogenous pyrogens: some concepts have changed 203 Fig. 1 . Pathways for fever in bacterial infections. 1. Infection can be local or systemic in which Gram-positive or Gram-negative organisms release cellwall products such as endotoxins, peptidoglycans, teichoic acids and others. Also, enterotoxins from Staphylococcus aureus and others products from Gram-positive organisms are released. 2. Gaining access to the circulation, for example in pneumonia entering the pulmonary vein and exiting via the carotid artery, microbial products reach the organum vasculosum laminae terminalis (OVLT) of the hypothalamus. The endothelium of the OVLT expresses TLR receptors and microbial products such as endotoxins bind to their respective TLR on the OVLT and activate the endothelium. 3. Microbial products also bind to TLR on phagocytic cells (macrophages, neutrophils, Kupffer cells) or to TLR on systemic endothelial cells. Pyrogenic cytokines IL-1, TNF-α, IL-6 and other cytokines are synthesized, processed, released and gain access to the circulation. In the case of enterotoxins, binding occurs on the T-cell receptor (in which case enterotoxins are called superantigens) resulting in production IL-1 and TNF-α. 4. These pyrogenic cytokines enter the circulation and bind to their respective cytokine receptors on the OVLT. 5. Activation of TLR and cytokine receptors induce COX-2, which results in synthesis of PGE 2 on the brain side of the OVLT. Increases in brain PGE 2 stimulate the release of cAMP and other neurotransmitters triggering thermosensitive neurons in the thermoregulatory center to raise the hypothalamic thermostatic set point. 6. Neuronal signals to the cortex initiate behavioral changes in humans to conserve body heat (posturing, clothing and others). 7. Hypothalamic signals activate peripheral efferent nerves to blood vessels via the sympathetic pathways. 8. Vasoconstriction of the blood vessels supplying the peripheral circulation decrease heat loss and core temperature increases (measured as fever). The resulting increase in blood temperature is detected by the hypothalamic center, which maintains these mechanisms of heat conservation (and behavioral changes) until hypothalamic PGE 2 levels fall (as a result of inhibitors of COX-2 and/or COX-3). Alternatively, COX-2 synthesis decreases as a result of absence of cytokine or TLR-driven signals at the level of the OVLT receptors. since IFN-γ inhibits LPS-and IL-1-induced PGE 2 . 24, 25 However, similarities between IFN-α and IL-6 may explain the pyrogenic nature of interferons. Despite IL-18 being a member of the IL-1 family and the IL-18 receptor also being a member of the IL-1 receptor family, IL-18 is not pyrogenic in humans, rabbits, rats and mice. 6, 26, 27 IL-18 does not induce COX-2 in monocytes or epithelial cells, 25, 28 whereas IL-1 is a potent inducer of COX-2 in these same cells. The fever due to IL-2 is thought to be secondary to induction of TNF-α. 29 
PYROGENIC CYTOKINES IN HUMANS

Interleukin-1
The historical background of the identification of IL-1 as a fever-producing cytokine is detailed in the sections found at the end of this review. The most convincing experiment that IL-1 was pyrogenic was the induction of a rapid-onset fever in mice, rabbits, rats, guinea pigs and humans following a single injection of the recombinant human or other mammalian IL-1, either IL-1β or IL-1α. Since recombinant cytokines are expressed in Escherichia coli, considerable caution needed to be employed to exclude the involvement of contaminating bacterial endotoxins in the recombinant preparations. Endotoxin evokes fever in rabbits at concentrations as low as 10 ng/kg and in humans even lower doses of 1 ng/kg are pyrogenic. 30, 31 Since endotoxin present in these recombinant IL-1 preparations (30-60 pg/mg) represents < 1/20,000,000 of the weight, the amount injected is < 1/10,000 of the minimal pyrogenic dose of endotoxin for rabbits. Furthermore, the fever produced by such preparations was unaffected by polymyxin B, which blocks the pyrogenic effect of E. coli endotoxin. Finally, fever is also elicited by IL-1 in C3H/HeJ endotoxinresistant mice. 32 IL-1β also produced fever in mice deficient in IL-1β. 33 In rabbits, the most sensitive species, 10 ng/kg of either IL-1α or IL-1β produced fever. 21 Although the systemic effects of IL-1 have been studied in animals, there are also ample data on the effects and sensitivity to IL-1 in humans. IL-1α or IL-1β has been injected into patients with various solid tumors, as part of a reconstitution strategy in bone marrow transplantation, or to treat cancer. Acute toxicities of either IL-1α or IL-1β were greater following intravenous compared to subcutaneous injection; subcutaneous injection was associated with significant local pain, erythema and swelling. 34 Chills and fever are observed in nearly all patients, even in the 1 ng/kg dose group. 35 At 10-30 ng/kg, all patients experience chills and fever. Even a 30-min infusion of IL-1β at 3 ng/kg induces fever and leukocytosis. 36 The febrile responses increase in magnitude with increasing doses of IL-1. [37] [38] [39] Not unexpectedly, chills and fever were abated with indomethacin treatment. 40 In patients receiving either IL-1α or IL-1β, nearly all subjects experienced significant hypotension at doses of 100 ng/kg or greater. Systolic blood pressure fell steadily and reached a nadir of 90 mmHg or less 3-5 h after the infusion of IL-1. Most patients required intravenous pressors. The hypotension is likely due to induction of nitric oxide, which was observed in subjects receiving only 3 ng/kg of IL-1β. 36 At 30-100 ng/kg of IL-1β, patients exhibited a sharp increase in cortisol levels 2-3 h after the injection. Similar increases were noted in patients injected with IL-1α. In 13 of 17 patients given IL-1β, there was a fall in serum glucose within the first hour of administration and in 11 patients, glucose fell to 70 mg/100 ml or lower. 41 In addition, there were increases in ACTH and thyroid stimulating hormone but a decrease in testosterone. 42 Not unexpectedly, IL-1 infusion into humans significantly increased circulating IL-6 levels in a dosedependent fashion. 42 At a dose of 30 ng/kg, mean IL-6 levels were 500 pg/ml, 4 h after IL-1 (baseline < 50 pg/ml) and 8000 pg/ml after a dose of 300 ng/kg. In another study, infusion of 30 ng/kg of IL-1α induced elevated IL-6 levels within 2 h. 43 These elevations in IL-6 are associated with a rise in C-reactive protein and a decrease in albumin. In two studies, one with IL-1α 43 and one with IL-1β, 44 rapid increases in circulating IL-1 receptor antagonist (IL-1Ra) and TNF soluble receptors (p55 and p75) were observed following a 30-min intravenous infusion.
IL-6 is clearly a pyrogenic cytokine
IL-6 administration in humans causes fever but unlike IL-1, microgram/kilogram doses are needed compared to nanogram/kilogram for IL-1. There have been multiple reports of elevated IL-6 levels in a variety of human diseases and in various human body fluids such as plasma, cerebrospinal fluid and joint fluids. IL-6 gene expression is, in part, under the control of several exogenous pyrogens but also IL-1 and TNF. 45 In fact, IL-1 and particularly IL-1 plus TNF are very potent stimulators of IL-6 gene expression and protein translation. Therefore, IL-6 is often elevated in conditions where IL-1 and TNF have been synthesized. Mice deficient in IL-1β do not produce IL-6 and have no fever when given an inflammatory disease. 46 IL-6 has biological and physical characteristics which clearly distinguish this cytokine from IL-1. For example, in the rabbit assay, 50-100-fold more IL-6 is needed for a monophonic fever compared to IL-1. 21 From a clinical standpoint, during most febrile diseases, several pyrogenic cytokines are produced and likely contribute to the febrile response. These now include a family of cytokines using the cell signaling apparatus, gp130. 47 Cytokines using this receptor are pyrogenic and currently they include IL-6 and CNTF, 22 producing fever in humans as well as in experimental animals. Interestingly, the gp130 signaling complex for IL-11, although being similar to that of CNTF and IL-6, does not result in fever in rabbits or humans. In fact, IL-11, like IL-6 48, 49 and CNTF, 50 suppresses the production of pyrogenic cytokines such as IL-1 and TNF. 51 IL-6, like IL-1, is a hematopoietic growth factor and treatment with IL-6 increases peripheral neutrophil counts in bone marrow transplant patients. 52, 53 Fever is also a property of IL-6 in these studies but occurs at doses 100-fold greater than that for IL-1β. IL-1 and TNF-α infusions in humans induce circulating IL-6 in humans within a few hours following the initiation of either cytokine; moreover, the fall in IL-6 levels following the administration of anti-TNF-α antibodies is wellestablished in patients with rheumatoid arthritis. 54 In humans with septic shock, there is a dose-dependent fall in serum IL-6 levels within 24 h of initiating an infusion of IL-1Ra (also know by its generic name, anakinra), whereas in placebo-treated patients, IL-6 levels continue to rise. 55 Therefore, the observation that IL-6 is IL-1-and TNF-α-dependent is an important concept for the pathogenesis of fever. In the conscious cat and in the absence of fever, IL-6 is usually below the threshold of a sensitive bioassay; however, during a continuous intravenous infusion of IL-1β at doses eliciting a sustained fever, IL-6 levels increased in the cerebrospinal fluid but there was no effect on concentrations of TNF-α. 56 IL-6 is pyrogenic in humans and rabbits but neither cytokine induces COX-2 from peripheral cells. 21 In rabbits, both glycosylated and non-glycosylated forms of recombinant human IL-6 produce fever but glycosylated IL-6 was more pyrogenic than the non-glycosylated form and there was no evidence of synergy in the production of fever when IL-6 and IL-1 were given simultaneously. IL-6 fever was blocked by prior administration of the cyclooxygenase inhibitor ibuprofen. IL-6 was also pyrogenic in the cat by either the systemic or the intraventricular route. However, in both species, IL-6 was 50-100-fold less pyrogenic than IL-1β. When given intracerebroventricularly to cats, IL-6 produced an increase in PGE 2 levels of the cerebrospinal fluid in parallel with the rise in body temperature. However, IL-6 from 150-1500 ng/ml did not increase mononuclear cell PGE 2 production in vitro whereas IL-1β induced 20-30fold increases in PGE 2 at 10 ng/ml. 21 Others have shown that IL-6 does not stimulate PGE 2 formation through increased COX-2 expression. 57 Thus, peripherally, IL-6 does not act as a pro-inflammatory cytokine. Similarly, CNTF is pyrogenic in both humans and rabbits, but does not induce COX-2. 50 How does IL-6 induce PGE 2 ? The fever due to IL-6 is reduced by most cyclooxygenase inhibitors, strongly suggesting that PGE 2 is induced by IL-6; furthermore, mice deficient in COX-2 do not manifest fever to IL-1β or LPS, whether injected intraperitoneally or directly into the brain via the intracerebroventricular route. 5, 7 However, the discovery of COX-3 may be relevant to this issue. COX-3 is an isoform of the COX-1 gene, which can undergo alternative splicing generating different isoforms. Each isoform is capable of converting arachidonic acid to PGE 2 . In the brain, the isoform COX-3 is expressed primarily in the cerebral cortex. 58 Although there are no studies showing a direct induction of COX-3 by IL-6, up-regulation of COX-3 may account for the mechanism by which IL-6 induces PGE 2 and fever. This concept would also be consistent with the ability of acetaminophen (paracetamol) to act as a potent antipyretic 59 despite the fact that acetomenophen does not inhibit COX-2.
The roles of IL-1β and IL-6 have been studied in mice deficient in genes for these cytokines. Mice have been injected with LPS as a model of systemic inflammation whereas subcutaneous injection of turpentine has been used to induce local inflammation by formation of an abscess. 60 The abscess contains large numbers of inflammatory cells and necrotic tissue. In IL-1β deficient mice, there was significantly less fever after subcutaneous turpentine. 46 There was also significantly less IL-6 and acute phase proteins. In contrast, the systemic injection of LPS results in fever in IL-1β deficient mice no different from that in wild-type mice. 61 In many ways, these differences illustrate the issue at hand. The local abscess formed by turpentine is a source of IL-1β produced by the infiltrating inflammatory cells in wild-type mice but in IL-1β deficient mice, the inability to produce IL-1β results in the absence of fever. This serves as an example of a TLR-independent, cytokine-mediated fever. In the case of LPS-induced fever, the absence of IL-1β has no effect on the febrile response because systemic LPS triggers its own TLR-4 receptors in the brain and initiates fever. The latter is an example of a cytokine-independent, TLR-mediated fever. One can assume that fever associated with sterile inflammatory processes such as trauma is exclusively cytokine-mediated.
In the turpentine model, there was no fever in IL-6 knockout mice, consistent with the downstream dependency of IL-6 on IL-1β in this model. 46 These studies concluded that IL-1β drives IL-6 production and that IL-6 is needed for fever induced by a non-microbial product such as turpentine.
TNF-α is a pyrogenic cytokine
At 100-200 ng/kg, recombinant human TNF-α produces the typical endogenous pyrogen-fever pattern in rabbits and C3H/HeJ mice. The rapid rise in body temperature that occurs in rabbits after an intravenous injection of TNF-α is indistinguishable from that produced by either form of recombinant IL-1, albeit at 10-fold lower doses. 20 However, at a dose of 10 µg/kg (50-100 times the minimal pyrogenic dose), TNF-α evokes a second fever peak 3-4 h after the injection. Plasma taken from rabbits during the second fever peak contains circulating IL-1; this finding formed the basis of the concept that TNF-α induces IL-1 in vivo. 20 Humans given intravenous infusions of TNF-α develop rigors and fever but these are reported at doses starting at 100 ng/kg and reaching 1500 ng/kg without a clear dose-response in the febrile response. [62] [63] [64] [65] The fever induced in humans is rapid and is associated with generalized malaise and joint pain. By comparison, humans injected intravenously with IL-1α or IL-1β at doses as low as 3-10 ng/kg develop rapid onset of chills and fever. 34, [36] [37] [38] [39] 41, 42, 66 Therefore, in humans and rabbits, IL-1 is a more potent pyrogen than TNF-α.
Another distinguishing characteristic of TNF-α versus IL-1 is the effects on leukocytosis. Unlike TNF-α, IL-1 is a true hematopoietic cytokine 67 whereas TNF-α suppresses bone marrow precursors. Humans given intravenous injections of either IL-1α or IL-1β have a rapid increase in circulating neutrophils (reviewed by Dinarello 68 ). In fact, IL-1 is an established bone-marrow stimulant and recombinant IL-1 has been used therapeutically in patients undergoing bone-marrow transplantation. 34, [37] [38] [39] 41, 42, 66 There are no studies using TNF-α in the same clinical setting. In humans injected with only 3 ng/kg of IL-1β, there is a brisk neutrophilia within 1 h. 36 In humans infused with TNF-α at doses ranging from 100 ng to 15,000 ng/kg, there is a profound neutropenia. [63] [64] [65] 69, 70 
PYROGENIC CYTOKINES AND THE
ACUTE-PHASE RESPONSE
Although fever is primarily associated with infectious diseases, the febrile response is, in fact, a prominent component of many inflammatory and immunologically mediated diseases; fever frequently accompanies certain malignancies. However, fever is hardly an isolated event. Increases in the total and relative numbers of circulating young neutrophils can often be present. In addition, many febrile illnesses are accompanied by an increase in the synthesis of a variety of hepatic acutephase proteins. 71 These include antiproteases, haptoglobin, several complement components, fibrinogen, ceruloplasmin, and ferritin. 71 There can also be 100-or 1000-fold increases of special acute-phase proteins such as C-reactive protein and serum amyloid A protein. 71 The dramatic increase in the rate of synthesis of these proteins occurs despite the fact that hepatic albumin synthesis is markedly reduced; indeed, the host is often in negative nitrogen balance. In general, the onset of fever accompanied by these hematological and metabolic changes is frequently referred to as the acute-phase response.
The acute-phase response is a systemic, generalized reaction although most disease processes that induce it are localized. There has been considerable speculation that the role of acute-phase proteins is to help contain pathogens and their toxins and to inactivate microbial proteases and highly reactive oxygen metabolites. More than one leukocyte product is now identified as mediating acute-phase hepatic protein synthesis. IL-1, TNF, IL-6, IL-11, oncostatin M, CNTF, cardiotropin-1 and leukemia-inducing factor possess the ability to stimulate the hepatocyte to increase gene expression for various acute phase proteins as well as suppress the synthesis of several 'house-hold' proteins. 71 These latter proteins include lipoprotein lipase, albumin and cytochrome p450. 72 The ability of these cytokines to suppress gene expression for these commonly produced molecules accounts, in part, for the altered lipid and drug metabolism observed in patients with acute or chronic infections or diseases.
Unlike IL-1 and TNF, IL-6 does not possess the same spectrum of pro-inflammatory properties. In fact, because IL-6 is a prominent inducer of hepatic acutephase proteins, the acute phase-inducing properties of IL-6 are often viewed as anti-inflammatory. Since many acute-phase hepatic proteins are either oxygen scavengers or anti-proteases, there has been considerable speculation that IL-6 can be protective in some models (reviewed by Tilg et al. 73 ). In human peripheral blood mononuclear cells (PBMCs), IL-6 suppresses LPS-and PHA-induced TNF. 48, 49 Studies in IL-6 deficient mice provide supporting evidence for the in vitro observation that IL-6 suppresses TNF-α. Following an injection of LPS, levels of TNF-α were several-fold higher in IL-6 deficient mice compared with wild-type mice. 74, 75 In addition, IL-6 deficient mice injected intracerebroventricularly with LPS exhibited an increase in TNF production that was primarily observed in the peripheral circulation but not in the central nervous system. 75 These studies are consistent with the concept that IL-6 can act as an anti-inflammatory cytokine.
PYROGENIC CYTOKINES AND THE
THERMOREGULATORY CENTER
Pyrogenic cytokines injected into the circulation or reaching the brain via the systemic circulation from peripheral tissues do not readily penetrate the bloodbrain barrier or enter the brain tissue during the time frame of the febrile response (see Fig. 1 ). Studies show that peripherally injected pyrogenic cytokines radiolabeled with 125 I are found in the brain substance, primarily in the choroid organs, but only several hours or days after the febrile event. Radiolabeled LPS also does not pass readily into the central nervous system following peripheral injection. Several studies performed in the 1980s revealed that pyrogenic cytokines have their major effect on the rich vascular network close to the cluster of neurons in the pre-optic/anterior hypothalamus. Called the circumventricular organs and abbreviated OVLT (organum vasculosum laminae terminalis), these areas form a partial blood-brain barrier on each side of the preoptic area, each being supplied by the internal carotid artery. The vascular nature of the OVLT is fenestrated. Bilateral ablation of the OVLT prevents fever after a peripheral injection of endogenous or exogenous pyrogens. This finding forms the basis of the concept that pyrogens arriving from peripheral sites trigger their respective receptors on the blood-side of the endothelium of the OVLT. 76 Animals with bilaterally ablations of the OVLT do develop fever to pyrogens injected directly into the cerebral ventricles, suggesting that receptors for pyrogens in brain tissue itself are capable of transmitting a signal to the thermoregulatory center, bypassing the OVLT. Although ablation of the OVLT likely results in a breakdown of the blood-brain barrier, the lack of fever production from peripheral pyrogens indicates that simple passage of pyrogens into the damaged area of the OVLT is not sufficient to initiate a febrile response.
The endothelial cells of the OVLT offer a unique pathway for peripheral pyrogens to affect the thermoregulatory center (see Fig. 1 ). It is likely that pyrogens arriving from the carotid artery activate their respective receptors on the endothelial cells releasing arachidonic acid, which is rapidly converted to PGE 2 . This and other metabolites of cyclooxygenase then diffuse the few millimeters into the pre-optic/anterior hypothalamic region and initiate fever. The OVLT is not as tight as the bloodbrain barrier in the cortex but is still a barrier. Because of the restrictive nature of the blood-brain barrier, it is likely that PGE 2 and other metabolites of arachidonic acid are released from the brain-side of these endothelial cells and subsequently induce the release of neurotransmitters in the brain. Since prostaglandins are not suitable as neurotransmitters, true neurotransmitters must transmit a signal. PGE 2 is known to increase levels of cAMP, which has neurotransmitter properties in brain tissue and has been implicated in fever production. 12, 13, 77, 78 Not unexpectedly, many studies reveal that the fever induced by IL-1β or LPS can be blocked by depletion of central nervous system neurotransmitters.
THE HYPOTHALAMIC ENDOTHELIUM AS A TARGET FOR
FEVER PRODUCTION BY PYROGENIC CYTOKINES AND LPS
In view of the role of the OVLT in the initiation of fever after systemic injection of pyrogens, it is important to note that two pyrogenic cytokines, IL-1 and TNF, have profound effects on endothelial cell function. IL-1 and TNF activate human endothelial cells in vitro to synthesize and release PGI 2 and PGE 2 . A 10-fold increase in PGI 2 release follows exposure to less than 1 ng/ml IL-1β. 79 Although these two arachidonate metabolites increase blood flow, IL-1 and TNF also orchestrate a cascade of cellular and biochemical events that lead to vascular congestion, clot formation, and cellular infiltration. One way in which IL-1 and TNF initiate these events is by stimulating the plasma membrane of endothelial cells so that neutrophils, monocytes, and lymphocytes adhere avidly. IL-1, at relatively low concentrations, activates cultured vascular endothelial cells in < 1 h by inducing the expression of intercellular adhesion molecule 1. 80 IL-1-induced and TNF-induced increases in procoagulant activity on the endothelial cell surface serve to increase coagulation. There is also evidence that IL-1 and TNF induce the production of a plasminogen activator inhibitor. These events lead to activation of factor VIII and thrombin for the initiation of clotting. Taken together, these effects of IL-1 and TNF lead to decreased blood flow in vessels and increased accumulation of leukocytes and platelets. Since IL-1 is a stimulator of thromboxane release from neutrophils, activated neutrophils adhering to endothelial cells are likely to increase platelet aggregation. Thromboxane release from adherent neutrophils may also contribute to fever since thromboxane levels in the third cerebral ventricle rise with the early increase in IL-1-mediated fever. 81 IL-1 stimulates the release of platelet-activating factor from endothelial cells. These IL-1 and TNF-induced effects on vascular tissue would make the endothelial surface in the OVLT a prime site of action in the initiation of fever.
LPS is no stranger to endothelial cell function. In fact, nearly all of the biological effects of IL-1 and/or TNF on endothelial cell functions are also reported for LPS. Of considerable relevance to the present concept, TLR-4 expression has been demonstrated in various vascularrich areas of the brain, including the leptomeninges, choroid plexus, subfornical organ and the OVLT. 82 In the OVLT, the expression was constitutive and also included CD14. Following administration of systemic LPS or IL-1β, the level of expression of TLR-4 did not change. The authors of the study concluded that the constitutive expression of both CD14 and TLR-4 may account for responses in the brain from peripheral endotoxemia, particularly in vascular networks where the blood brain barrier is less restricted. 82 
Febrile responses to IL-1, low and high doses of LPS
As shown in Figure 2 , the doses of LPS that cause fever when injected into rabbits are in the same order of magnitude as those of IL-1 or TNF. For example, an intravenous bolus injection of 10 ng/kg LPS into rabbits produces a monophasic fever of 1°C and 10 ng/kg of human IL-1β also produces the same fever pattern. 21 The difference between the febrile response to the two pyrogens is found in the time of latency and the time of peak temperature elevation. IL-1β-induced fever begins within 10 min after intravenous bolus injection whereas LPS latency is approximately 30 min. IL-1β-induced fever reaches peak elevation at 50 min whereas LPSinduced fever is maximal at 90 min. Although these differences are not at first dramatic, they are highly consistent from laboratory to laboratory and are also observed using recombinant human or rabbit IL-1 or LPS from different bacterial species. One may conclude that the receptors for IL-1 and LPS (TLR-4) are present on the hypothalamic vascular network but that signal transduction and the release of PGE 2 (or other neurotransmitters) is faster following IL-1β compared to LPS. Both LPS-and IL-1-induced fevers are suppressed by inhibitors of COX-1 and COX-2. 5, 7 As discussed, COX-3 also appears to participate in the febrile response in that inhibition of COX-3 takes place with the well-established antipyretic acetaminophen (paracetamol). 59 
Role of the vagus nerve in the febrile response
Several studies have implicated the role of the afferent vagal nerves in the induction of fever. Using a method known as microdialysis to measure local PGE 2 in the thermoregulatory center of the brain, guinea pigs were injected intravenously with LPS. In subdiaphragmatically vagotomized guinea pigs, there were no increases in local PGE 2 levels and no fevers. 14 In rats, contrary data were reported in that vagotomy resulted in increased PGE 2 in the cerebral spinal fluid. 83 In another study, three different branches of the vagus nerve of rats were severed -the celiac, gastric and hepatic branches. After recovery, the rats were injected intravenously with LPS and only rats with a severed hepatic branch failed to develop LPS fever. 84 Intravenous LPS, as in the rabbit, produces an early fever peak (1 hour after LPS) as well as a later fever (5 h). The later fever peak is cytokine-mediated. In vagotomized rats, the early fever peak was present but the later fever peak was reduced 2.5-fold. 85 This suggests that the later, cytokinemediated fever is affected by vagotomy. The effect of vagotomy was reported to be primarily after a low dose of LPS whereas higher amounts of LPS cause fever independent of the vagal afferents. 86 Most studies of the effect of vagotomy have used the intraperitoneal route of administration. However, it appears that vagotomy has little effect in suppressing fever when LPS is injected intramuscularly, whereas fever produced by intraperitoneal LPS is affected. 87, 88 Unexpectedly, total vagotomy did Fever curves in rabbits. The intravenous bolus injection of IL-1β, LPS at 10 ng/kg or LPS at 10 mg/kg are shown over time. Core temperature was measured by in-dwelling rectal thermistors. These are representative curves derived from several studies over the past 30 years. Both IL-1β and low dose (10 ng/kg) of LPS produced nearly identical monophasic fevers within 10-15 min following the intravenous injection. The small time difference between the peak fever for each pyrogen is highly reproducible. Three hours after a large dose of LPS (10 µg/kg), circulating plasma was obtained and then passively injected into rabbits made resistant to endotoxin. The monophasic, brisk fever (see inset) demonstrated that the circulating plasma contained the 'endogenous' pyrogen. This method of passive transfer of circulating plasma during the second fever peak of a bi-phasic fever was commonly used to demonstrate the in vivo induction of an endogenous pyrogen following the injection of any exogenous pyrogen of unrelated physical or chemical structure. 2 The method was also used to demonstrate fever due to pre-formed antigen-antibody complexes, which activated complement following intravenous injection. The injection of antigens in previously sensitized animals also induced biphasic fevers with circulating endogenous pyrogens after 3 h. [196] [197] [198] The discovery that TNF-α induced circulating IL-1 was also made using passive transfer of plasma 3 h after rabbits were injected with recombinant TNF-α at 10 mg/kg. 20 not suppress circulating IL-6 after intraperitoneal LPS. 87 Subdiaphragmatic vagotomy reduces the pyrogenicity of IL-1β as well as LPS but does not influence circadian sleep or core temperature. 89 Tracey and colleagues have studied the effect of the vagus efferents on cytokine production and inflammation. It appears that electrical stimulation of the vagus nerve in the rat results in reduced LPS-induced TNF-α from the liver as well as protection from the lethal effects of LPS. 90 The vagal neurotransmitter, acetylcholine, inhibited the release of TNF-α, IL-1β and IL-18 but not IL-10 from peritoneal macrophages. 90 The mechanism by which acetylcholine inhibits cytokine production is via the triggering of the nicotinic acetylcholine receptor alpha-7 subunit. 91 There is no electrical stimulation-mediated suppression of TNF-α production from peritoneal macrophages of mice deficient in the nicotinic acetylcholine receptor alpha-7 subunit. 91 These results on the anti-inflammatory effects of vagus nerve stimulation and acetylcholine are in contrast to decreased fever and PGE 2 in rats with vagotomies. In addition, the assessment of these pathways is difficult to ascertain clinically since patients with vagotomies continue to develop fever when infected.
LPS FEVER IN RABBITS AND HUMANS IN THE PRESENCE OF IL-1 AND/OR TNF-α α BLOCKADE
Studies in the rabbit
The advantage of the IL-1 receptor antagonist (IL-1Ra) is that it exhibits no species specificity, similar to IL-1 itself. Therefore, it was possible to block IL-1-induced fever in rabbits or mice regardless of the source of IL-1 or IL-1Ra. When infused into rabbits, human IL-1Ra completely prevented the febrile response to human or rabbit IL-1. 92, 93 With these results, it was clear that the pyrogenic property of IL-1 was preventable by blocking IL-1 receptors in or near the thermoregulatory centers. However, even using a high level and of constant intravenous infusion of IL-1Ra in rabbits, which blocked all IL-1 receptors, there was no attenuation of the fever due to either intravenously injected LPS or a preparation of heat-killed Staphylococcus epidermidis. 93 . These results suggested that in the presence of total IL-1 receptor blockade, LPS or S. epidermidis were able to produce fever independently of IL-1. It remains possible that these exogenous pyrogens may induce the intermediate production of IL-6; however, at least 50% of the IL-6 produced following the administration of LPS or S. epidermidis is IL-1β dependent. 94 Therefore, some diminution of fever would have been expected. Nevertheless, since LPS induces fever in IL-6 deficient mice, 60 one can assume that LPS acts independently of cytokines for fever production.
Studies in humans
Similar studies were also performed in humans. Humans offer a unique opportunity because of the previously established safety of LPS and IL-1Ra in human volunteers. In fact, intravenous infusions of 10 mg/kg of IL-1Ra were shown to be safe and not to affect any metabolic, hematological or hormonal homeostatic parameter. 95 In patients with bone-marrow transplants, daily infusion of IL-1Ra for several days at 2 mg/kg/h was without ill effects. 96, 97 The febrile response to a bolus injection of 3-4 ng/kg of LPS in humans has been thoroughly established. 30, [98] [99] [100] [101] [102] In addition to fever, several host responses to intravenous LPS were also available for study. For example, LPS in humans induces a characteristic fall in lymphocytes and a rapid rise in circulating neutrophils. 30, 103 Healthy human male volunteers were admitted to a clinical study unit and were without food or water for 12 h. An intravenous line was placed at 8 a.m. and at 8:30 a.m., a constant 3-h infusion of IL-1Ra was begun at either 1, 5 or 10 mg/kg. 104 This infusion results in mean peak IL-1Ra blood levels of 2400, 15,300 and 29,200 ng/ml, respectively, for each dose. 104 Control subjects received a constant infusion of saline and both groups were blinded. At 9 a.m., a bolus injection of LPS (3 ng/kg) was given in the opposite arm. There was no change in the febrile response following LPS in any of the three doses of IL-1Ra. 104 Figure 3 illustrates the fever curve in the group receiving 10 mg/kg of IL-1Ra. Two hours after the LPS injection, Infection, fever, and exogenous and endogenous pyrogens: some concepts have changed 209 Fig. 3 . Febrile response in humans to LPS and to LPS plus IL-1Ra. Data are taken from the studies described by Granowitz et al. 104 Human volunteers were injected with 3 ng/kg of E. coli LPS (O113 from the US Food and Drug Administration, lot EC-5) by intravenous bolus injection and simultaneously, a 3-h intravenous infusion of IL-1Ra was started. Controls (five subjects) received LPS plus a 3-h intravenous infusion of saline. The total doses of IL-1Ra administered were 1 mg/kg (3 subjects), 5 mg/kg (3 subjects) and 10 mg/kg (3 subjects). All subjects developed fever to LPS plus each dose of IL-1Ra. The data in the graph represent the mean change in rectal temperature of three volunteers receiving LPS plus a constant infusion of IL-1Ra at 10 mg/kg; the control group represents the mean change in rectal temperature of 5 volunteers injected with LPS plus a constant infusion of saline. The asterisk indicates P < 0.05 at that time point only. The mean peak concentration of IL-1Ra in the volunteers was 2920 ± 720 ng/ml. 104 the group receiving IL-1Ra exhibited a statistically significant greater rise in core temperature compared to the saline controls. This difference was not observed in the groups receiving 1 or 5 mg/kg of IL-1Ra. The biological significance of the increase is unknown.
In the same study, assessment of other effects of LPS were studied. IL-1Ra did, in fact, reduce the leukocytic response to LPS by 35% as well as immunological parameters by approximately 50%. 104 There were also decreases in circulating cytokines IL-1β, IL-6, IL-8, TNFα and granulocyte-macrophage colony stimulating factor in the group treated with 10 mg/kg of IL-1Ra. 104 However, these decreases (~30-40%) did not reach statistical significance due to the small number of subjects in the study. Therefore, it was concluded that IL-1, in part, mediated non-febrile responses of LPS but that LPS produced fever in the presence of total IL-1 receptor blockade. These findings were similar to those observed in the rabbit studies.
A second study was performed in healthy human subjects given a constant intravenous infusion of IL-1Ra and a bolus injection of a higher does of LPS (4 ng/kg). 105 In that study, IL-1Ra was co-infused at a dose of 133 mg/h for 6 h following the bolus injection of LPS. The mean peak IL-1Ra level was 34,000 ng/ml. There were no statistically significant differences in core temperature, hemodynamic parameters, energy expenditure or endocrine responses between the six subjects receiving LPS plus a saline infusion and six subjects receiving the co-infusion. 105 Both groups were blinded. However, there was a statistically significant decrease (P < 0.05) in the subjective severity of LPS-induced symptoms recorded by the subjects during the study. 105 Changes in severity of symptoms was not studied during the first study until after the study was completed. 104 Similar studies were carried out by Suffredini and coworkers. 99 In order to block IL-1 activity, neutralization of IL-1 was achieved employing a co-infusion LPS plus the soluble (extracellular) form of the type I IL-1 receptor (sIL-1RI). Two doses of sIL-1RI were tested in healthy volunteers. Compared to placebo infusion, LPS-induced increases in circulating IL-1β and IL-1Ra. 106 However, the complexes of sIL-1RI with endogenous IL-1Ra were elevated 43-fold. This observation was consistent with the high affinity of the sIL-1RI for IL-1Ra. 68 There was also a higher level of LPS-induced TNF-α, IL-8 and C-reactive protein (CRP). Although sIL-1RI reduced the severity of LPS-induced chills, 99 there were no reductions in temperature, hemodynamic responses, platelet or leukocyte counts. The fever pattern of LPS plus the soluble IL-1 receptor compared to the pattern of LPS plus placebo was not different. It remains unclear why there was a reduction solely in the severity of the chills, but this observation is consistent with the findings of Van Zee et al., 105 who reported a decrease in the severity of LPS-induced symptoms by IL-1Ra. The failure to alter the febrile response to LPS with a constant infusion of IL-1Ra or the soluble IL-1 receptor is consistent with the results observed in the rabbit using LPS plus a constant infusion of IL-1Ra. 93 The TNF soluble receptor p75 dimeric construct linked to the Fc domain of IgG1 (sTNFR:Fc) is highly effective for neutralizing the biological effects of TNF in patients with rheumatoid arthritis, 107 psoriasis 108 and other autoimmune diseases. 109 However, as with patients receiving IL-1Ra or anti-TNF-α monoclonal antibodies for rheumatoid arthritis, in the presence of bacterial or opportunistic infections, these patients exhibit a febrile response and there does not seem to be a significant reduction in fever despite the fact that high levels of these anti-cytokines are present in the circulation. The effects of sTNFR:Fc were tested in human subjects injected with LPS. Two doses were used -10 µg/m 2 and 60 µg/m 2 . Although the bioassay for TNF activity in the plasma revealed neutralization, the concentration of TNF-α immunoreactivity increased dose-dependently. Levels of LPS-induced IL-1β as well as IL-1Ra, granulocyte-colony stimulating factor and IL-8 were decreased by sTNFR:Fc co-infusion. However, there were no changes in levels of macrophage inflammatory protein-1 alpha or IL-10. The systemic and hemodynamic responses to LPS were not reduced by sTNFR:Fc; although the febrile response was delayed, it was not diminished. The authors concluded that 'the inflammatory response to endotoxin can escape from high levels of circulating TNF-blocking activity and redundant pathways, independent of circulating TNF, can sustain inflammation and clinical responses caused by acute endotoxemia'. 101 The studies in humans summarized above were carriedout under highly controlled conditions in healthy volunteers in whom the dose of LPS and the infusion of cytokine blockers were optimal and clinical measurements were carefully monitored. However, the failure of blocking cytokines to reduce the pyrogenicity of LPS had already been observed in patients enrolled in clinical trials of IL-1Ra or anti-TNF-α antibodies for treating sepsis and septic shock. Most of the studies employed entry criteria that included fever. Following the start of the infusion of either IL-1Ra, 55, 110, 111 anti-TNF-α monoclonal antibodies 112--115 or soluble TNF receptors, [116] [117] [118] there are no reports of rapid defervesence. However, in most of these trials, circulating IL-6 falls with 24 h of initiating the anti-cytokine infusion compared to placebo-treated patients. Complicating the interpretation of the studies in septic patients are various interventions in intensive care units to reduce fever either pharmacologically or by physical means.
PYROGENIC CYTOKINES AND FEVER IN
AUTOIMMUNE DISEASES
It should be remembered that many febrile diseases are not caused by bacteremia or endotoxemia and, therefore, are not mediated by TLR triggering. Thus the concept remains that pyrogenic cytokines produced at sites of inflammation distant from the hypothalamus gain access to the systemic circulation and mediate the fever. These would be considered pure cytokine-mediated fevers rather than infectionrelated fever, which would be a combination of both cytokine and TLR mechanisms. For example, pure cytokine-mediated fevers would result from multiple trauma, cerebrovascular accidents, myocardial infarctions, transfusion reactions, and several auto-immune diseases. Using a murine model of a turpentine-induced sterile abscess, blocking antibodies to the IL-1 receptor type I prevents the fever, the increase in IL-6 and the rise in acute-phase proteins. 119 The sterile abscess contains activated macrophages and neutrophils and cellular debris from the muscle injury. In the same model, there is no fever, no elevation of IL-6 and no acute phase protein response in IL-1β deficient mice. 46, 60 
Immune-mediated fevers
These are fevers associated with diseases where an immune response to an antigen takes place in a sensitized individual. The best example is transfusion reactions. In that case, it is likely that antigen-antibody complexes activate complement. However, fever associated with Mycobacterium tuberculosis infection is also likely a cytokine-mediated event and not mediated by TLR. The M. tuberculosis products, which can bind to TLR-2, are unlikely to reach the hypothalamus since the organism is intracellular and also walled-off in a granuloma. The granuloma is comprised of transformed macrophagic cells and T-cells and pyrogenic cytokines produced from these cells likely elicit the fever.
Fever in Still's disease
Still's disease in children and systemic juvenile rheumatoid arthritis are highly febrile diseases. Adult-onset Still's disease (AOSD) is a particularly febrile disease and many patients are first evaluated for fever of unknown origin. 120 The clinical features of AOSD include intermittent, but often high spiking, fevers, a unique evanescent rash and arthritis. There is also a neutrophilic leukocytosis. Also highly characteristic of the disease are high levels of C-reactive protein (CRP) and ferritin. Some patients with AOSD are similar to patients with macrophage activation syndrome. 121 This is also a highly febrile disease. AOSD is associated with elevated levels of serum IL-1β, TNF-α, IL-6 and, more recently, IL-18. 122, 123 However, in any disease, assigning causality of a particular cytokine as contributing to the disease manifestations or pathology is determined by specific blockade and not by correlations of a cytokine serum or tissue level and disease severity. It is apparent that TNFα plays a role in several manifestations of AOSD since patients exhibit a rapid response upon intravenous infu-sion of the neutralizing monoclonal antibody to TNF-α, infliximab. [124] [125] [126] [127] [128] [129] But, AOSD patients refractory to conventional therapies of corticosteroids and methotrexate also experience a rapid resolution of fever and a reduction of the systemic and local manifestations of the disease within hours of the initial subcutaneous injection of IL-1Ra. 130 Others have reported similar results. 131 These responses to IL-1Ra are not unexpected since blocking TNF-α will reduce IL-1 production. Therefore, it is likely that the response in AOSD to anti-TNF-α is due to a reduction in IL-1. 130 
IL-1 specific febrile disease due to mutations in the NALP3 gene
Diseases such as rheumatoid arthritis show significant improvement with the blocking of different cytokines. However, there are genetically inherited diseases, which are uniquely mediated by IL-1. These are Muckle-Wells syndrome (MWS), 132 familial cold autoinflammatory syndrome (FCAS), [133] [134] [135] [136] and neonatal-onset multisystem inflammatory disease (NOMID). TNF blockers have little or no effect in alleviating the manifestations of these genetically inherited diseases. In general, reports of humans with various inflammatory diseases often make an association with a particular cytokine, and commonly, disease severity correlates with elevated cellular production or circulating levels. However, even highly significant correlations do not prove causation and IL-6 correlations with disease severity are a classic example. For instance, in patients with septic shock, blood levels of IL-6 are highly correlated with mortality but IL-6 causes neither hypotension nor triggers any of the pathological changes in septic humans.
Humans with Muckle-Wells syndrome, a rare autosomal dominant disease, suffer from recurrent fevers, neutrophilia, elevated acute phase proteins, painful arthritis and skin rashes. The genetic defect in these patients is found in a gene encoding NALP3, which is a member of a family of proteins involved in the processing of inactive caspases to active caspases. 137 Mutations in NALP3 affect the processing of IL-1β. 138 Upon treatment with anakinra (generic term for IL-1Ra), there is a rapid and near complete reduction in each of the inflammatory manifestations of the syndrome such as fever, neutrophilia, serum amyloid A, C-reactive protein and thrombocytosis. 132, 139 The rapid response to IL-1 receptor blockade demonstrates that the local and systemic manifestations of these syndromes are due to IL-1 since IL-1Ra only blocks IL-1 activity. Importantly, the clinical, hematological and biochemical changes of the syndrome not limited to this rare syndrome but are common to most infectious and autoimmune diseases. From these observations, one concludes that endogenous IL-1 is unquestionably a key mediator of fever and of systemic and local inflammation. In the case of the single amino acid mutation in Muckle-Wells syndrome, the processing of the inactive IL-1β precursor to an active cytokine results in spontaneous release of IL-1β from monocytes of affected subjects. 138 Patients with mutations in the NALP3 gene exhibit more than a single phenotype. For example, most subjects with these mutations report the onset of systemic disease during mild, upper respiratory tract viral infections or following trauma. Other subjects have a disease triggered by exposure to cold and called familial cold autoinflammatory syndrome (FCAS). In these patients, the mutation is L353P and the affected individuals exhibit recurrent bouts of fever, neutrophilia, rash, arthralgia and generalized fatigue within a few hours of cold exposure, including air conditioned rooms. 140 Although there is no detectable increase in circulating IL-1β levels in these patients, IL-6 levels are elevated. Skin biopsies from the affected areas reveal resident macrophages as well as infiltrating leukocytes staining for IL-1β but not in unaffected skin biopsies. 140 When subjects were pre-treated with a single injection of anakinra prior to cold exposure, fever, leukocytosis and circulating IL-6 levels were absent. 140 Moreover, the generalized fatigue abated. It is presently unknown how cold exposure triggers increased IL-1β gene expression and synthesis in affected subjects, but similar to all humans with mutations in NALP3, the defect results in increased processing of the inactive IL-1β precursor to an active form following cleavage by caspase-1. 138,140 Fig. 4 . Dysregulation of IL-1β processing and secretion in familial Mediterranean fever (FMF). Top group: the IL-1β inflammasome. 137 Following stimulation of macrophages, large amounts of the IL-1β precursor are synthesized but most remains intracellularly as inactive molecules. Processing of the IL-1β precursor into an active cytokine and secretion from the cell requires active caspase-1. However, activation of caspase-1 is under tight control by a protein called pyrin. Pyrin binds to ASC (apoptosis-associated Speck-like protein containing a caspase recruitment domain), an essential component of the activation of pro-caspase-1 to active caspase-1, and this binding inhibits the activation of the IL-1β inflammasome. Lower group, left. Despite the ability of pyrin to bind to and inhibit ASC, during activation of macrophages, this inhibition is overcome and active caspase-1 is able to cleave the IL-1β precursor subsequently into biologically active IL-1β, which is released from the cell. Lower group, right. Patients with FMF have a mutation in the pyrin protein. This mutation results in a truncated version of the protein; as a result, the truncated pyrin is inefficient in its ability to inhibit ASC. Without a fully active ASC, there is increased processing and secretion of active IL-1β. Mice with truncated pyrin, such that there is no longer inhibition of ASC, produce greater amounts of mature IL-1β and develop a greater febrile response. 142 In humans, the mutation is inherited and the resulting increased processing of IL-1β results in local inflammation as well as fever.
Familial Mediterranean fever (FMF) is perhaps the epitome of a non-infectious, genetically inherited febrile disease. The disease is characterized by periodic, but not regular, bouts of fever and serositis associated with leukocytosis, primarily neutrophilic. 141 The disease is transmitted as an autosomal recessive trait with mutations in the C-terminal of a protein termed pyrin. 142 Pyrin is involved with the caspase-1 pathways of IL-1β processing and secretion. Treatment of FMF with colchicine markedly reduces the frequency of the attacks and this may be due to reduced IL-1-mediated macrophage activation. 143, 144 Blocking IL-1 activity is likely to abate the manifestations of acute attacks. FMF is not the same disease as hyper IgD syndrome, which is common in The Netherlands, but which like FMF is characterized by periodic bouts of fever.
Fever and FMF
The FMF mutations in the protein pyrin are associated with increased IL-1β-associated inflammation. Pyrin shares an N-terminal sequence identity with ASC, the adaptor protein, which comprises the IL-1β inflammasome, 138 affecting the secretion of IL-1β. To mimic the gene defect in FMF, mice with a truncated C-terminal domain in pyrin were generated and when challenged with LPS, exhibited a greater febrile response and lethality compared to control mice. 142 Macrophages from these mice released greater amounts of processed IL-1β, which was due to apparently greater caspase-1 activity. 142 As shown in Figure 4 , normal pyrin inhibits caspase-1 by binding to ASC, a known caspase-1 activator. The lack of the C-terminal domain of pyrin in these mice results is a loss of intracellular suppression of caspase-1 activity. This is consistent with the concept that less than 20% of IL-1β is normally processed and released from LPS-stimulated monocytes. 48 It is clear that the default mode in LPS-stimulated monocytes is to limit the activation of caspase-1. The ability of full-length pyrin to bind ASC may be one of the mechanisms that contribute to this default mechanism. Similar to patients with the NALP3 mutations, minor stresses such as cold ambient air or viral infections trigger gene expression and translation of the IL-1β precursor; but, in the absence of endogenous caspase-1 inhibition, a greater amount of the IL-1β precursors are processed by caspase-1 and more severe inflammation takes place, including febrile episodes and inflammation of serosal surfaces. Other studies have shown that mutations in pyrin-binding cytoskeletal proteins present in patients with pyodermalike autoinflammatory syndromes can have a dominantnegative effect on the pyrin activity, resulting in increased secretion of IL-1β. 145 In a recent study of 72 patients with a clinical history of rheumatic-like diseases since childhood, a significant number (30%) were found to have one or two mutations in the FMF gene locus compared to a control group without the mutations. 146 Assuming the mutations affect inflammatory processes by increasing the processing or secretion of IL-1β, then their disease activity should be reduced by blocking IL-1 activity.
TNF-mediated, inherited febrile diseases
There are two diseases with recurrent febrile episodes associated with systemic inflammation: hyper IgD syndrome is one of these. In an international study of 50 patients, it was found that attacks of high-spiking fevers were present and occurred every 4-6 weeks. Like FMF, abdominal pain often accompanied the attacks. Interestingly, it was found in this cohort that a recent immunization was associated with the attack. 147 Levels of serum IgD were greater than 100 U/ml in 82% of the patients. Hyper IgD shares with systemic-onset juvenile rheumatoid arthritis, adult-onset Still's disease, and FMA similar local and systemic manifestations of febrile diseases in the absence of infection. However, infections or other immunological stress pathways can trigger each of these.
Incubation of peripheral blood monocytes with serum from patients with hyper IgD syndrome induces IL-1β and TNF-α production as well as IL-1Ra. The magnitude of stimulation was dose-dependent and revealed a 30-fold increase in TNF-α and a 150-fold increase in IL-1β. 148 Incubation of monocytes with serum from IgD patients in the presence of LPS augmented production of cytokines, mostly of TNF-α. The authors concluded that IgD is a potent inducer of TNF-α.
Hyper IgD is caused by various mutations in the enzyme controlling cholesterol synthesis. The mevalonate kinase gene also controls the synthesis of isoprenoids. Urinary mevalonate levels are elevated in the syndrome. Others have shown that levels of TNF-α are also elevated. Patients with the syndrome have been treated with etanercept, the p75 soluble TNF receptor. 149 Treatment with etanercept reduced the severity of the attacks as well as the frequency of the episodes. In six patients with the syndrome, treatment with simvastatin reduced urinary levels of mevalonic acid and reduced the number of days for each attack. 150 The second TNF-mediated febrile disease is TNFR1associated periodic syndrome (also termed TRAPS). This syndrome is characterized recurrent fevers with localizing inflammatory manifestations. The genetic basis of the syndrome is found in the extracellular domain of the TNF p55 receptor. Six different mutations have been described. 151, 152 These are inherited as autosomal dominant diseases. Most of the mutations involve the disulfide bonds of the receptor. In general, the soluble p55 receptor, which results from a serine protease cleavage of the cell bound receptor is present in the serum of healthy individuals at concentrations of 3-5 ng/ml 153 but in patients with these mutations, the concentrations of the soluble receptor are reduced. 151 It has been proposed that the reduction in the shedding of the cellbound p55 receptor deprives the host of a natural buffer against TNF-α produced during routine cellular stresses. In fact, reduced shedding in these patients was associated with increased numbers of p55 receptors on neutrophils. 151 The authors proposed that both reduced serum levels of the soluble forms of the receptor as well as increased cell-bound receptor form the basis of the disease. However, since there is no evidence that the levels of soluble p55 receptor in health contribute as a buffer to TNF-α activity, the more likely explanation is that increased receptors on cells are the basis of the disease. In treating patients with etanercept (the generic term for the soluble form of the p75 TNF receptor), it is necessary to reach concentrations of 3-4 mg/ml for clinical efficacy, a 100-fold excess over the normal values. Etanercept in these patients reduces the disease severity. 152
CONCLUSIONS
There are ample data in experimental animals as well as in humans that the injection of IL-1α, IL-1β, IL-6, CNTF or TNF-α results in fever, even at exceedingly low doses of a few nanogram per kilogram. In the case of IL-1 and TNF-α, blocking these cytokines in animals or humans does not diminish the febrile response to LPS and patients being treated with IL-1Ra, anti-TNF-α antibodies or soluble TNF receptors, are febrile when infected. One can conclude that LPS and other microbial products can cause fever independent of these cytokines presumably by their direct action on TLR on the vascular network supplying the thermoregulatory centers in the hypothalamus. These conclusions assume that the rich network of blood vessels supplying the anterior hypothalamus contains TLR-4-expressing endothelial cells, which bind LPS and transmit a signal for COX-2 expression. One also assumes that receptors for products of Gram-positive organisms can trigger TLR-2 receptors in a similar fashion and initiate fever.
As shown in Figure 1 , LPS entering the circulation encounters TLR-4 receptors on the OVLT, triggering PGE 2 synthesis. This is the result of the well-established ability of LPS to induce COX-2. 154 PGE 2 , in turn, stimulates the release of cAMP in the hypothalamus, near the thermoregulatory center. cAMP can then act as a neurotransmitter raising the set-point of the thermoregulatory neurons. Other neurotransmitters also participate. As the raised set-point increases, core temperature increases via vasocontriction by peripheral efferent pathways, which reduces heat loss.
The fact that LPS and other microbial agents can trigger their respective TLR and induce fever does not diminish the role of TLR is the production of pyrogenic cytokines. In fact, during infection, both mechanisms likely contribute to fever. The relative contributions of TLR-mediated or cytokine-mediated COX-2 expression are likely dependent on the particular infection. Critical to both mechanisms is the requirement for any pyrogen to reach the hypothalamic area via the circulation. PGE 2 , produced from activated leukocytes in tissues, can enter the circulation but is inactivated in the pulmonary vascular bed and hence does not reach the brain via the carotid circulation.
Clinically, the fever induced by pyrogenic cytokines is indistinguishable from those induced by LPS. Of the many genes triggered by pyrogenic cytokines, LPS or Gram-positive products, COX-2 and perhaps also COX-3 orchestrate the release of neurotransmitters such as cAMP, which are responsible for raising the thermostatic set-point. This hypothesis is supported by the observation that COX-2 deficient mice do not develop a fever following administration of LPS. 5, 7 Do these findings negate the decades-long concept that exogenous pyrogens cause fever by the intermediate production of endogenous pyrogens? No, because exogenous pyrogens (microbial products) are potent inducers of pyrogenic cytokines. However, the new data do call for a modification of the concept since the identification of a mechanism by which exogenous pyrogens such as LPS reaching the hypothalamic center can directly trigger their respective receptors, without a strict requirement for the synthesis of endogenous pyrogenic cytokines.
ADDITIONAL HISTORY ON RESEARCH INTO THE
PATHOGENESIS OF FEVER
An appreciation of early investigators
For centuries, fever has been associated with leukocytic infiltrates and written documentation dates back to experimental studies of the 19th century. Roman military physicians also wrote of the resolution of fever in soldiers once pus was drained. This subject, as well as the role of fever in history, have been reviewed by Atkins. 2, 155 It was increasing clear during the 19th century that 'pus' contained a pyrogenic substance. The first papers on pus being pyrogenic came from the Russian émigré Menkin, who injected rabbits with supernatants from peritoneal exudates from other rabbits. The fevers that Menkin reported from the injection of these fluids was most likely due to contaminating endotoxins. The first experimental demonstration that an endotoxin-free protein material derived from leukocytes was a pyrogen was described in 1948 by Paul Beeson. 1 Those studies were performed using activated leukocytes derived from sterile peritonitis produced in rabbits. Because most of these cells were granulocytes, the pyrogenic material was originally called granulocytic or leukocytic pyrogen and later used interchangeably with the term endogenous pyrogen In this review, the term endogenous pyrogen (EP) has been used for granulocytic or leukocytic pyrogen. After incubation for a few hours in saline, the pyrogenic activity was spontaneously released from the cells, which previously had infiltrated into the peritoneal cavity. Therefore, these cells had been activated in vivo and then released the pyrogenic protein upon ex vivo shortterm culture.
The biological assay for EP activity was, and remains today, a highly consistent rapid rise in rectal temperature reaching peak elevation within 50-60 min following intravenous bolus injection into rabbits. The fever peak is also monophasic in that there is no second fever peak (Fig. 2) . In contrast, peak fever occurring after 60 min or biphasic fevers are characteristic of several bacterial products, particularly LPS. Low doses of LPS produce a monophasic fever, which is similar to the monophasic fever of EP, although the fever peak occurs 30 min later than EP. Higher doses of LPS characteristically produce a bi-phasic fever (Fig. 2) . Although discussed below in detail, it is worth noting here that the signaling apparatus of the hypothalamic TLR for LPS as well as the receptors for pyrogenic cytokines are temporally close (50-90 min) . Serum taken during the second peak of fever, that is characteristic of higher doses of LPS, contains EP. 2 One can conclude that the first fever peak is the result of the direct effect of LPS on the hypothalamic thermoregulatory center via TLR-4 whereas the second fever peak represents the fever due to cytokines such as IL-1 or IL-6, induced by TLR-4 from peripheral macrophages. It is unlikely that the plasma circulating during the second fever peak contains significant TNF-α since LPSinduced TNF-α in humans, rabbits and mice is transiently elevated at 90 min and absent at 3 h.
Early work on the nature of endogenous pyrogens
Initially, little was known about the chemical nature of EP except that it was a heat-labile protein (destroyed at 90°C). A great amount of the initial work on EP came from the laboratories of Barry Wood at Washington University in St Louis with Elisha Atkins and later at Johns Hopkins with Patrick Murphy. Murphy and the late Barry Wood were the first to describe the physical characteristics of a purified form of an EP from rabbit acute peritoneal exudate cells. 156 This rabbit EP had a molecular weight of 14-15 kDa and a neutral isoelectric point (pI of 7). In many ways, the research on fever and EP provided the first insights into the existence of cytokines and their role in disease.
Studies of human peripheral blood revealed that EP was synthesized de novo and not pre-formed as was the case with rabbit peritoneal exudate cells. [157] [158] [159] Other studies demonstrated that EP was also produced from human monocytic leukemia cells 160 and Hodgkin's and lymphoma cells. 161 For example, there is now a large literature on the production of cytokines from synovial cells of patients with rheumatoid arthritis, but using the EP assay of fever in rabbits, activity was first shown to be produced from human synovial cell explants by the late Phyllis Bodel, 162 long before the current interest in the role of cytokines in rheumatoid arthritis. In addition, the well-known ability of taxol and other agents that disrupt microtubule assembly to induce IL-1 was first reported by Bodel using EP production from human monocytes stimulated with colchicine. 163 Later studies confirmed that work using cytokine assays. 164 In fact, much of what can be called the early studies on IL-1 and related cytokines was reported by the late Phyllis Bodel using EP assays.
The group of scientists working with the late Sheldon Wolff made considerable contributions to the understanding of responses to LPS injected into humans. 30, 165 Wolff was a pioneer in understanding the human responses to an intravenous injection of LPS into healthy humans. 103, [166] [167] [168] [169] [170] Again, it is not an exaggeration to state that much of what we now identify as cytokine biology was first investigated as EP. For example, circulating factors in volunteers injected with LPS induced a brisk leukocytosis when later re-infused into the same subject. 170 It is likely that Wolff and Dale had identified granulocyte colony stimulating factor. For many years, Sheldon Wolff and colleagues also studied the recurrent febrile inflammatory condition FMF. 143, 144 As described above, the gene for FMF has been identified and the production of IL-1, not TNF-α or IL-6, is dysregulated in that disease. 142, 145 There is more than one EP Early studies had assumed that EP was a single molecule, but in 1974 two distinct endogenous pyrogens from human monocytes were characterized: both had molecular weights in the 15-20 kDa range. The initial biochemical studies on human and rabbit EP described an activity with a neutral isoelectric focusing point. However, the second EP had an isoelectric focusing point between 5.1-5.5 and was clearly distinct from the EP with an isoelectric focusing point (pI) of 6.8-7.0. 171 Using macrophage-derived rabbit EP, the second, acidically charged form was described. 172, 173 The antiserum to rabbit neutral EP did not block the pyrogenic activity of the acidic forms and it was concluded that these two forms of EP were immunologically distinct. 172 Although an explanation for this molecular heterogeneity was unclear at that time, these findings introduced the concept that there was more than one chemically distinct EP. Today, the issue has been clearly resolved and the pI 5 form of EP has been identified as IL-1α whereas the pI 7 form is IL-1β. In addition to the two different iso-electric forms of EP, a large molecular weight EP, estimated on gel-filtration to be 38 kDa, 171 was also described. This larger EP now is thought to be the precursors of IL-1α. The existence of precursor forms of IL-1 was later described for human IL-1β 174 and mouse IL-1α. 175 However, precursor IL-1β present in the supernatants of human monocytes is biologically inactive unless cleaved by extracellular protease such as proteinase-3. 176 Therefore, the EP activity of the large molecular weight EP from human monocytes was likely IL-1α, which is active as a precursor molecule. The pI 7 form of human EP was purified to apparent homogeneity in 1977. 177 
EP possesses multiple biological activities
It was later found that these EPs possessed additional distinctive biological properties apart from their ability to evoke fever. The concept that EP possessed multiple properties was derived from the work of Kampschmidt and co-workers, who showed that the acute phase-inducing properties of 'leukocytic endogenous mediator' (LEM) were not separable from endogenous pyrogen activity. 178, 179 It was also reported that the pI 7 human EP induced serum amyloid A protein production. 180 Thus, by the mid-1970s, EP was well on the way to being a thoroughly defined molecule(s) in terms of both chemical characterization and identification of non-pyrogenic biological properties. From today's viewpoint, the multiple biological activities of EP/LEM can be considered the birth of 'cytokine biology' with EP being the first cytokine described.
Entrance of immunologists to the field
In 1972, Gery and Waksman 181 described a property present in the supernatants of stimulated mouse macrophages that augmented T-lymphocyte responses to either mitogens or specific antigens. Early reports on the chemical nature of 'lymphocyte-activating factor' (LAF) indicated a striking similarity to EP. In 1976/1977, it became clear to those working on the characterization of EPs that LAF was remarkably similar to EP not only at the biochemical level but also in terms of cellular sources, kinetics of production, and spectrum of agents inducing synthesis. In fact, during this time, neutralizing antibodies to human EP also neutralized human LAF. 182 In 1979, we proposed that EP and LAF were the same molecule. 182 Similar evidence was published by Patrick Murphy. 173 Later, names such as EP, LAF, LEM and mononuclear cell factor 183 were abandoned for a new name, IL-1.
The interleukin nomenclature
The realization that EP possessed a broad spectrum of biological activities involving the pathogenesis of acutephase responses and lymphocyte-activating properties increased interest in EP. The interleukin nomenclature was invented to resolve the issue that there were two activities with lymphocyte-activating properties, one from macrophages (termed IL-1) and one from lymphocytes (termed IL-2). At the time this nomenclature was proposed, it was thought that leukocytes were both the common source and target tissues. Hence, the term 'interleukin' was used to connote 'between leukocytes'. However, it was also known that the monocyte product IL-1 also possessed non-leukocyte targets such as brain, liver, muscle and connective tissues. Nevertheless, IL-1 was a convenient term given the plethora of other names used to describe the varied biological activities. It should be noted that despite the nomenclature, there was no amino acid sequence analysis of either IL-1 or IL-2, and these terms were primarily used to describe biological activities.
It was a highly contentious time for IL-1 researchers who reported that a single molecule caused fever, induced hepatic acute phase proteins, activated lymphocytes and up-regulated prostanoid synthesis. 184 Criticism was focused on the lack of recombinant IL-1 to prove that a single molecule could, in fact, possess such a wide and varied spectrum of biological activities. The motivation to 'clone' IL-1 and test recombinant IL-1 for multiple biological activities was to either prove or disprove the concept. In 1984, a review of IL-1 predicted that IL-1 was capable of multiple biological effects. 184 
cDNA for IL-1 identified: recombinant IL-1 causes fever and possesses multiple biological effects
With the ability to produce recombinant proteins, the confirmation of the biological activity(s) of a specific protein was deemed necessary in recombinant form. This had been more the case with the pyrogenicity of IL-1 than any similar protein purified to date. In 1984, cDNAs for mouse IL-1α 175 and human IL-1β 174 were cloned. Experiments with recombinant IL-1 demonstrated that IL-1 indeed was pyrogenic 32 and mediated many components of the acute-phase response. The amount of recombinant IL-1 needed to produce a monophasic fever in rabbits was in the range of 10-20 ng/kg, 21 close to the estimated specific activity of the purified protein from human monocytes 177 and rabbit peritoneal exudates cells. 156, 173 Thus, the existence of a single, endogenously produced molecule (in this case IL-1), was proven to cause fever.
Pioneers in the chemistry and pyrogenicity of LPS
During the early 1960s, a number of advances had been made concerning the chemistry of LPS by Otto Westphal, Otto Lüderitz, Chris Galanos and Ernst Rietschel. 185 Lipid A had been identified as the biologically active component of LPS and when coupled to serum albumin, was shown to cause fever in rabbits. 186, 187 Unlike EP, nearly limitless amounts of LPS were available for purification and resulted in the identification of lipid A as possessing the active component for pyrogenicity. In contrast, mammalian cell cultures required serum factors complicating production and purification. Two camps of investigators were forming at that time: one group of mostly Americans claimed that protein-bound LPS was pyrogenic because it induced the production of EP and the other group, mostly Germans, held that lipid A of LPS, bound to protein, directly acted on the hypothalamic thermoregulatory center to produce fever. The arguments for each group were presented in the classic review by Atkins. 2 Both groups, however, agreed that EP was not LPS. Knowledge of cytokine biology increased dramatically in the 1980s, not only in the biological scope of the work but also in molecular techniques of protein purification, gene cloning and the production of recombinant cytokines such as IL-1, TNFα and IL-6. Furthermore, immunological tools such as monoclonal antibodies resulted in specific measurements of various cytokines in human disease. In neurobiological laboratories, researchers employed recombinant IL-1 and other cytokines rather than LPS to study the thermosensitive neurons. At the same time, research into LPS as a pyrogenic molecule was, by comparison, stalled. Only studies of the LPS-resistant C3HeJ mouse continued to provide a sufficient tool to study the role of LPS in fever. Today, we recognize that this mouse strain has a spontaneous mutation in the TLR-4 and hence does not develop fever to LPS. 3 Other exogenous pyrogens from Gram-positive organisms were even less studied for pyrogenicity because of the paucity of pure reagents.
With the discovery of TLR, the concept that microbial products from Gram-positive as well as Gram-negative organisms were pyrogens in their own right, without the need for intermediate cytokines, re-opened the area to research. Today, one can look back at the work of these pioneers in LPS chemistry and biology [185] [186] [187] [188] [189] with a great deal of respect and admiration. Although these studies on the pyrogenicity of LPS were primarily conducted in rabbits and sheep, 190, 191 pioneers such as Sheldon Wolff and Sheldon Greisman used human subjects, mostly volunteers, to investigate the human febrile responses to intravenously injected LPS in humans. 30, 31, 103, 165, 167, 192, 193 Greisman and colleagues made major contributions to the phenomenon known as pyrogenic tolerance. 31, 194, 195 Studies by Wolff and colleagues also focused on 'non-specific resistance to infection' induced by LPS. Today 'non-specific resistance to infection' is called innate immunity.
